Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,109.50GBp
11:29am EST
Change (% chg)

102.50p (+2.56%)
Prev Close
4,007.00p
Open
4,028.50p
Day's High
4,117.00p
Day's Low
4,011.00p
Volume
3,026,119
Avg. Vol
2,848,784
52-wk High
5,505.00p
52-wk Low
3,680.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease... (more)

Overall

Beta: 0.82
Market Cap(Mil.): £50,911.63
Shares Outstanding(Mil.): 1,265.05
Dividend: 68.70
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 26.07 30.04 30.65
EPS (TTM): 1.54 -- --
ROI: 5.70 15.86 15.23
ROE: 16.21 16.96 16.56

AstraZeneca pill slashes lung cancer progression in study

LONDON AstraZeneca's pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial, lifting prospects for a drug that is key to the company's lofty long-term sales goals.

Dec 06 2016

AstraZeneca in broad drug deal with Bicycle worth up to $1 billion

LONDON AstraZeneca has signed a wide-ranging deal with private biotech firm Bicycle Therapeutics to develop a novel class of small molecule medicines for treating respiratory, cardiovascular and metabolic diseases.

Dec 01 2016

AstraZeneca in broad drug deal with Bicycle worth up to $1 billion

LONDON AstraZeneca has signed a wide-ranging deal with private biotech firm Bicycle Therapeutics to develop a novel class of small molecule medicines for treating respiratory, cardiovascular and metabolic diseases.

Dec 01 2016

Britain's FTSE looks set for third straight week of gains

LONDON, Nov 25 Britain's top share index looked set for a third straight week of gains on Friday, with its heavily weighted commodity sector benefiting from bets on rising inflation even as a broader equity rally stalled.

Nov 25 2016

GSK chases Astra with start of big anemia drug trials

LONDON GlaxoSmithKline has started pivotal trials of an experimental anemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude.

Nov 24 2016

GSK chases Astra with start of big anaemia drug trials

LONDON, Nov 24 GlaxoSmithKline has started pivotal trials of an experimental anaemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude.

Nov 24 2016

UPDATE 1-AstraZeneca cleared to resume enrolment in cancer drug trials

* Trials involve AstraZeneca's immunotherapy durvalumab (Adds shares, further details on immunotherapy)

Nov 22 2016

BRIEF-AstraZeneca resumes cancer trials after FDA lifts partial hold

* Astrazeneca head and neck cancer trials resume new patient enrolment as fda lifts partial clinical hold

Nov 22 2016

U.S. court upholds AstraZeneca, Ranbaxy win in Nexium antitrust trial

A U.S. appeals court upheld AstraZeneca Plc and Ranbaxy Laboratories' victory in a lawsuit accusing them of reaching an illegal deal to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium.

Nov 21 2016

U.S. court upholds AstraZeneca, Ranbaxy win in Nexium antitrust trial

Nov 21 A U.S. appeals court upheld AstraZeneca Plc and Ranbaxy Laboratories' victory in a lawsuit accusing them of reaching an illegal deal to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium.

Nov 21 2016

Earnings vs. Estimates